Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2009年3月2日 - 11:00PM
PRニュース・ワイアー (英語)
--BIO-Europe Spring(R) 2009 in Milan, Italy-- PT. RICHMOND, Calif.,
March 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.
(NASDAQ:TSPT) announced today that the Company will present at two
upcoming conferences: -- Glenn A. Oclassen, President and Chief
Executive Officer, will present at Bio-Europe Spring(R) 2009, to be
held at the Milano Convention Centre (MIC) in Milan on Tuesday,
March 17, 2009, at 4:30 p.m. CET (10:30 a.m. ET). -- Thomas P.
Soloway, Senior Vice President and Chief Financial Officer, will
present at the Cowen and Company 29th Annual Health Care
Conference, to be held at the Boston Marriott Copley Place in
Boston, MA, on Tuesday, March 17, 2009, at 9:30 a.m. ET. An audio
webcast of Mr. Soloway's presentation will be available live and
archived for 30 days at http://www.transcept.com/. About Transcept
Pharmaceuticals Transcept Pharmaceuticals is a specialty
pharmaceutical company focused on the development and
commercialization of proprietary products that address important
therapeutic needs in the field of neuroscience. On January 30,
2009, Transcept completed a merger with Novacea, Inc. As part of
the transaction, Novacea changed its name to "Transcept
Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The
combined company resources resulting from the merger are expected
to enable Transcept to successfully commercialize its lead product
candidate, Intermezzo(R). If approved, Intermezzo(R) is positioned
to be the first commercially available sleep aid specifically for
use in the middle of the night when patients awaken and have
difficulty returning to sleep. Intermezzo(R) Phase 3 clinical
trials have been completed and, on September 30, 2008, Transcept
submitted a New Drug Application (NDA) for Intermezzo(R) to the
U.S. Food and Drug Administration (FDA) which was accepted for
filing on December 15, 2008. The FDA has assigned a PDUFA date of
July 30, 2009, to the Intermezzo(R) NDA. For further information,
please visit the company's website at: http://www.transcept.com/.
Safe Harbor This press release contains forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995 (the "Act"). Transcept disclaims any intent or obligation to
update these forward-looking statements, and claims the protection
of the Safe Harbor for forward-looking statements contained in the
Act. Examples of such statements include, but are not limited to,
statements relating to Intermezzo(R) being the first commercially
available sleep aid in its target indication. Such statements are
based on management's current expectations, but actual results may
differ materially due to various risks and uncertainties,
including, but not limited to: positive results in clinical trials
may not be sufficient to obtain FDA approval; physician or patient
reluctance to use Intermezzo(R), if approved; potential alternative
therapies; maintaining adequate patent or trade secret protection
without violating the intellectual property rights of others; and
other difficulties or delays in, or unexpected expenses incurred in
connection with, obtaining regulatory approval, market acceptance
and commercialization of Intermezzo(R). Contacts: Transcept
Pharmaceuticals, Inc. Michael Gill Director of Communications (510)
215-3575 The Ruth Group Investors / Media Stephanie Carrington /
Jason Rando (646) 536-7017 / 7025 DATASOURCE: Transcept
Pharmaceuticals, Inc. CONTACT: Michael Gill, Director of
Communications of Transcept Pharmaceuticals, Inc., +1-510-215-3575,
; or Investors, Stephanie Carrington, +1-646-536-7017, , Media,
Jason Rando, +1-646-536-7025, , both of The Ruth Group for
Transcept Pharmaceuticals, Inc. Web Site: http://www.transoral.com/
Copyright